✨ Free AI Report
Kyverna Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Kyverna Therapeutics, Inc.
Company Research

Kyverna Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101, an autologous CD19 CAR T-cell therapy for stiff person syn...

Analyst-debate audio for Kyverna Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Kyverna Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Kyverna's strong Phase 2 efficacy data and pathway to potential first-in-class CAR-T approval for autoimmune disease positions it...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Cell Therapy / Immunotherapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Kyverna Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Kyverna Therapeutics, Inc. Overview

Pro stress-test →

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101, an autologous CD19 CAR T-cell therapy for stiff person syndrome, myasthenia gravis, lupus nephritis, multiple sclerosis, and systemic sclerosis. The company is pioneering a durable disease-clearing approach aiming for deep B cell depletion and an immune system reset to achieve treatment-free remission.

Strategic Profile

Pro stress-test →

Kyverna has experienced leadership from Kite Therapeutics veterans with proven CAR-T market expertise. The company maintains ample funding with cash runway extending well into 2027 without additional fundraising. The company has a license and collaboration agreement with Intellia Therapeutics to develop an allogeneic CD19 CAR T-cell product.

Competitive Landscape

Pro stress-test →

Kyverna is building presence in the biopharmaceutical landscape through innovative CAR T-cell technology, robust clinical strategy, and collaborative partnerships. Key competitors in CAR-T for autoimmune disease include Artiva Biotherapeutics, Cabaletta Bio, and other clinical-stage immunotherapy companies, though Kyverna appears positioned as a potential first-to-market for CAR-T in autoimmune indications.

Industry Context

Kyverna Therapeutics, Inc. operates in Biopharmaceuticals - Cell Therapy / Immunotherapy.

Key facts

Founded: 2018 · Headquarters: Emeryville, California · Revenue: $0 · Market cap: ~$93M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Kyverna Therapeutics, Inc..

  • Positive interim Phase 2 data in gMG demonstrated all primary and secondary endpoints with 100% of patients achieving rapid, robust disease reduction sustained through 24 weeks, positioning KYV-101 as potentially transformative therapy.
  • Landmark Phase 2 results in stiff person syndrome could enable miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease with BLA submission planned for 1H 2026.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Recent clinical update from Kyverna
  • December 2025Positive topline data from KYSA-8 Phase 2 trial in stiff person syndrome with 46% average symptom improvement
  • +1 moreTrack every material event for Kyverna Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Kyverna Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell TherapyDeveloping CAR-T therapies for autoimmune diseases→Hematopoietic Stem Cell TherapyDeveloping cell therapies for autoimmune diseases→Allogeneic CAR-T ResearchCollaboration partner for allogeneic CD19 CAR cell therapy→

Compare Kyverna Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Kyverna Therapeutics, Inc. operates in Biopharmaceuticals - Cell Therapy / Immunotherapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Cell Therapy / Immunotherapy research →
NEW · MCP server

Ask your AI assistant about Kyverna Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Kyverna Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Kyverna Therapeutics, Inc. do this quarter?”
“Is Kyverna Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Kyverna Therapeutics, Inc. do?+
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101, an autologous CD19 CAR T-cell therapy for stiff person syn...
What is Kyverna Therapeutics, Inc.'s Cyborg Score?+
Kyverna Therapeutics, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Kyverna Therapeutics, Inc.'s main competitors?+
Named competitors include CAR-T Cell Therapy, Hematopoietic Stem Cell Therapy, Allogeneic CAR-T Research. The full competitive landscape is in the AskCyborg report.
How can I get the full Kyverna Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Kyverna Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Kyverna Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.